Navigation Links
InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock
Date:11/5/2013

BRISBANE, Calif., Nov. 5, 2013 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has agreed to sell 6,500,000 shares of its common stock at a price to the public of $13.00 per share in an underwritten public offering.  InterMune has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock in connection with the offering.  InterMune estimates net proceeds from the offering to be approximately $79.6 million (assuming no exercise of the underwriters' option to purchase additional shares of common stock), after deducting underwriting discounts and commissions and estimated offering expenses.  InterMune intends to use the net proceeds from the offering to fund the commercialization of Esbriet® (pirfenidone) and its ASCEND clinical trial for U.S. registration of Esbriet, to advance the company's strategic initiatives including its new Esbriet formulations, its recently launched clinical trials supporting the use of Esbriet in idiopathic pulmonary fibrosis (IPF) and in potential new indications, its expanding anti-fibrotic research program with compounds intended to address IPF and other fibrotic diseases, and for general corporate purposes.  InterMune expects to close this transaction on or about November 12, 2013, subject to satisfaction of customary closing conditions. 

Goldman, Sachs & Co. and J. P. Morgan Securities LLC are acting as joint book-running managers of the offering.  JMP Securities LLC, Leerink Swann LLC, UBS Securities LLC and Wells Fargo Securities, LLC are acting as co-managers of the offering.  The offering is being conducted by means of a prospectus supplement filed as part of an effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on Form S-3.  Copies of the preliminary pr
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Andrew Powell Joins InterMune As Executive Vice President And General Counsel
2. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
3. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
4. InterMune To Release First Quarter Financial Results On April 24
5. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. InterMune To Release Third Quarter Financial Results On November 7
8. InterMune To Present At JMP Securities Healthcare Conference
9. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
10. InterMune to Present at J. P. Morgan Healthcare Conference
11. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 Follow us on ... young has groomed and nurtured anti-aging products and ... emphasis on appearance maintenance is benefitting the market ... protein obtained from the bacterium, Clostridium Botulinum, which ... relaxation. With cosmetic indications for botulinum toxin ranging ...
(Date:9/22/2014)... 22, 2014 FierceBiotech today announced its ... biotechnology companies of 2014. FierceBiotech editors John Carroll ... this year’s winners. Those selected are identified as ... the industry. , "It's always a lot ... Fierce 15 companies," said Carroll. "This year in particular ...
(Date:9/22/2014)... Sept. 22, 2014  Spherix Incorporated (SPEX) -- an intellectual ... intellectual property, today announced that the United States Patent & ... in the month of September that is part of a ... patent is: USRE45,121 , Application number: US 13/728,867 ... date: Dec 27, 2012 The listed inventors ...
(Date:9/20/2014)... 2014 HealthTronics, Inc. , ... radiology products and services, has signed a distribution ... Clinicon Corporation for its high precision laser ... minimally invasive, mobile, surgical technology—offering more choices for ... agreement, HealthTronics will make available Clinicon’s FDA-cleared SureLase™ ...
Breaking Biology Technology:Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 2Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 3FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3
... on Thursday announced that three Wisconsin businesses would receive ... Commerce Technology Assistance Grant (TAG) and Technology Venture Fund ... , Functional Biosciences, Inc. , is a ... It will receive a $250,000 TVF loan for work ...
... ads on their round, shiny stomachs as part of "tummy ... To some, this is "desperate branding" in action. , ... spot on the list of branding failures. These projects are ... weird processes. , ,Roy Disney said, "You need branding when ...
... summer. Business slows. Indeed, in Europe, where I find myself ... animation that will last until the first of September. People ... grasp weakens. , ,Or does it? , ,After a rare ... mountain in my inbox and a to-do list that had ...
Cached Biology Technology:A final word on branding 2A final word on branding 3A final word on branding 4A final word on branding 5Leaving it all behind 2
(Date:9/21/2014)... the University of California, San Diego, have developed a ... control the activity of genes based on sequences of ... its application to human embryonic cells in a paper ... , "All of our cells have the same blueprint, ... John Whitaker, lead author of the report. "Skin cells ...
(Date:9/21/2014)... -- Shellfish such as mussels and barnacles secrete very ... ship hulls, even underwater. Inspired by these natural adhesives, ... that could be used to repair ships or help ... new waterproof adhesives, the MIT researchers engineered bacteria to ... proteins as well as a bacterial protein found in ...
(Date:9/19/2014)... today by researchers from several Harvard University labs ... experienced and aspiring researchers with the intellectual raw ... made from soft, flexible materials. , With the ... other advances in manufacturing technology, soft robotics is ... drawn from conventional rigid robot design, but working ...
Breaking Biology News(10 mins):Program predicts placement of chemical tags that control gene activity 2Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3Soft robotics 'toolkit' features everything a robot-maker needs 2
... Not only land birds, but also some seabirds, ... example, circumnavigates the earth one and a half times ... about the migratory behaviour of seabirds as compared with ... Planck Institute for Ornithology have studied the migratory behaviour ...
... In a paradigm changing discovery, Plasmodium vivax ( ... historically thought to be resistant to the disease, those who ... red blood cells, according to researchers from Case Western Reserve ... of Health. In a study of more than 600 individuals ...
... experimental oral drug has lowered blood sugar levels and inflammation ... could someday be added to the arsenal of drugs used ... research. The drug consists of a synthetic molecule that ... inhibitory factor, or MIF. This protein is implicated in a ...
Cached Biology News:To the Antarctic or Brazil for new feathers 2To the Antarctic or Brazil for new feathers 3Duffy-negative blood types no longer protected from P. Vivax malaria 2Duffy-negative blood types no longer protected from P. Vivax malaria 3Study points to potential new drug for type 2 diabetes 2Study points to potential new drug for type 2 diabetes 3Study points to potential new drug for type 2 diabetes 4
... The Holten MaxiSafe 2010 Class II ... ergonomical working condition of comfort while ... efficiency and performance.,Refined operator, environment and ... both exhausted and recirculated air.,Bottom filters ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... Stand-96 is designed for paramagnetic bead precipitation ... ml PCR plates with no additional accessories. ... in a standard SBS 96-well microplate footprint. ... magnets guarantees easy and fast (as little ...
... circular clear acrylic chamber for complete visibility ... features microprocessor operation for precise mixing capability. ... Carousel rotates at 11 rpm; manufactured ... , Bottle Capacity - four 35 ...
Biology Products: